Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient

Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient

BackgroundAutoimmune adverse events are the most relevant risks of alemtuzumab therapy. We present a patient with relapsing-remitting multiple sclerosis, who developed adult-onset Still’s disease (AOSD) following alemtuzumab treatment.Case PresentationThe patient suffered from sore throat, swallowin...

Full description

Bibliographic Details
Main Authors: Julia Krämer, Tanja Krömer-Olbrisch, Heinz-Jürgen Lakomek, Peter D. Schellinger, Dirk Foell, Sven G. Meuth, Vera Straeten
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
Adult onset still disease
secondary autoimmunity
alemtuzumab
rituximab
anakinra
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.02099/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.02099/full

Similar Items